Home>>Signaling Pathways>> Proteases>> ACE>>Spirapril hydrochloride

Spirapril hydrochloride Sale

(Synonyms: 盐酸螺普利; SCH 33844 hydrochloride) 目录号 : GC64597

Spirapril (SCH 33844) hydrochloride 是一种有效的血管紧张素转换酶 (ACE) 抑制剂,具有降压作用。Spirapril hydrochloride 竞争性地与 ACE 结合,阻止血管紧张素I向血管紧张素 II 的转化。Spirapril hydrochloride 是螺普利拉的一种口服活性前药,可用于高血压、充血性心力衰竭的研究。

Spirapril hydrochloride Chemical Structure

Cas No.:94841-17-5

规格 价格 库存 购买数量
5 mg
¥2,790.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active prodrug of Spiraprilat and can be used for the research of hypertension, congestive heart failure[1].

Spirapril (feeding needle; 10 mg/kg; 3 weeks) decreases alcohol intake in TGM123 mice and dose not reduce the alcohol consumption in TLM mice. Spirapril shows a 40.2% reduction in ACE activity in brain membrane from treated-mice. It crosses the blood-brain barrier and suppresses the transgene effect in the experiments.[2]

[1]. Spirapril. Drugbank.
[2]. B Maul, et al. Alcohol consumption is controlled by angiotensin II. FASEB J

Chemical Properties

Cas No. 94841-17-5 SDF Download SDF
别名 盐酸螺普利; SCH 33844 hydrochloride
分子式 C22H31ClN2O5S2 分子量 503.07
溶解度 储存条件 4°C, away from moisture
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.9878 mL 9.939 mL 19.8779 mL
5 mM 0.3976 mL 1.9878 mL 3.9756 mL
10 mM 0.1988 mL 0.9939 mL 1.9878 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Drug interaction of Spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of Spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets

Arzneimittelforschung 2003;53(6):414-9.PMID:12872612DOI:10.1055/s-0031-1297129.

The potential influence of concomitantly administered hydrochlorothiazide (CAS 58-93-5) on the pharmacokinetics of spirapril (CAS 94841-17-5)/spiraprilat (CAS 83602-05-5) and of concomitantly administered spirapril on the pharmacokinetics of hydrochlorothiazide was investigated in an open, randomised, 3-way crossover study in 12 healthy male subjects. The test drug was a newly developed bi-layer tablet containing a fixed combination of Spirapril hydrochloride monohydrate and hydrochlorothiazide (Quadroplus). The reference formulations were tablets containing solely Spirapril hydrochloride monohydrate (Quadropril) or hydrochlorothiazide (produced exclusively for study medication). For spirapril, spiraprilat and hydrochlorothiazide the 90% confidence intervals of the AUC(0-infinity) as a measure for the extent of absorption were entirely included within the equivalence range of 0.8 to 1.25 and the 90% confidence intervals of the Cmax as a measure for the rate of absorption were entirely included within the extended equivalence range of 0.7 to 1.43. Therefore, bioequivalence was concluded for the test and reference formulations. The results suggest that hydrochlorothiazide does not interact in the fixed combination with the pharmacokinetics of spirapril and vice versa.